• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market

    5/22/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email

    SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company's silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market.

    SINTX remains focused on advancing silicon nitride technologies for medical applications; however, the material's broad utility allows for selective expansion into high-impact adjacent sectors. In line with this strategic expansion, the Company has formed a wholly-owned subsidiary that will have a dedicated management team focused on developing and commercializing agricultural and environmental technologies—signaling the official launch of SINTX Agribiotech, Inc.

    Market Opportunity

    The global antimicrobial fertilizer and crop protection market is projected to grow significantly, reaching up to $10.36 billion by 2030. SINTX intends to position its Si₃N₄ technology at the intersection of sustainability and high-performance crop protection within an industry increasingly focused on sustainable, eco-friendly solutions.

    Independent Path for Growth

    The new agribiotech subsidiary will operate independently from SINTX's medical device business, with its own development pipeline. This separation allows for focused resource allocation, technology validation in field settings, and potential partnerships or licensing opportunities with agricultural companies.

    "This is more than diversification—it's about unlocking the full potential of our core material," said Eric Olson. "We're establishing a clear path to deploy our Si₃N₄ into vineyards, orchards, farmlands and hydroponic facilities, potentially beginning with one of the most compelling use cases: wine production."

    Silicon Nitride: A Natural Defense Against Crop Disease

    Internal research previously published in Frontiers in Microbiology demonstrates that silicon nitride provides powerful antifungal protection against Plasmopara viticola, the pathogen responsible for grapevine downy mildew, one of the most devastating diseases affecting vineyards globally. The study demonstrated that treating grapevine varieties such as Cabernet Sauvignon and Cannonau with Si₃N₄ reduced the growth and sporulation of P. viticola by 80–90%, with complete protection observed in select trials.

    Unlike traditional fungicides, SINTX's Si₃N₄ formulation offers broad-spectrum antimicrobial action without damaging plant tissue or the surrounding environment—especially relevant as copper-based fungicides face increasing regulatory restrictions. (see: Frontiers in Microbiology, 2021)

    "Silicon nitride doesn't just inactivate pathogens—it can also prevent most infections altogether," said Eric Olson, Chairman and CEO of SINTX. "In our recent studies, silicon nitride exhibited no phytotoxicity, helped buffer environmental pH, and showed no evidence of cytotoxicity in humans. It's a sustainable, high-performance alternative to copper and chemical-based treatments in viticulture."

    For more information about SINTX Agribiotech or silicon nitride applications in medical or agriculture applications, please visit www.sintx.com.

    About SINTX Technologies, Inc.

    Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods.

    Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Forward looking statements include our belief that Si₃N₄ will be a sustainable, high-performance alternative to copper and chemical-based treatments in viticulture, our ability to position silicon nitride technology at the intersection of sustainability and high-performance crop protection , and our ability to eventually develop an effective crop protection product and successfully market such a product. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.

    Business and Media Inquiries for SINTX:

    SINTX Technologies

    801.839.3502

    [email protected]



    Primary Logo

    Get the next $SINT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

      Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

      6/24/25 8:30:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors

      New leadership and recapitalization to accelerate commercialization of proprietary silicon nitride technologies in medical and high-growth markets SALT LAKE CITY, Utah, June 12, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, today announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of its intellectual property portfolio. This follows the company's successful recapitalization in February 2025 and the restructure of its leadership team and Board of Directors. A Legacy of Innovatio

      6/12/25 9:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market

      SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company's silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market. SINTX remains focused on advancing silicon nitride technologies for medical applications; however, the material's broad utility allows for sel

      5/22/25 7:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care